<DOC>
	<DOCNO>NCT01508286</DOCNO>
	<brief_summary>The purpose early access program provide telaprevir patient specific type hepatitis C viral infection ( term 'genotype 1 ' ) expect benefit telaprevir-based therapy reside country telaprevir yet commercially available eligible enrollment clinical study telaprevir . The study also aim collect information safety adverse event telaprevir treatment combination peginterferon alfa ribavirin , typically used treat patient hepatitis C. In addition hepatitis C viral infection , patient study also diagnosis liver fibrosis compensate liver disease .</brief_summary>
	<brief_title>Early Access Program Telaprevir With Peginterferon Ribavirin Chronic Hepatitis C Subjects</brief_title>
	<detailed_description>This multicenter , multinational , open-label , non-comparative early access program design provide telaprevir patient infect hepatitis C virus genotype 1 , document diagnosis liver fibrosis compensate liver disease ( Child Pugh Grade A ) , expect benefit telaprevir-based therapy . Patients exclude eligible enrollment ongoing clinical study telaprevir . Enrollment patient study continue telaprevir becomes available reimbursement country patient resides September 2013 , whichever occur first , unless otherwise indicate per local regulation . During first 12 week study , patient receive telaprevir administer orally food every 8 hour combination peginterferon-alfa/ribavirin [ PEG-IFN-alfa/RBV ] ) . Patients treat Peg-IFN-alfa/RBV alone additional 12 36 week , base respond treatment ( assessed level hepatitis C viral RNA plasma , reflect number virus particle bloodstream ) and/or type patient ( patient severe fibrosis receive prior treatment previously relapse treatment , patient prior partial null response [ partially respond previous treatment ] , patient viral breakthrough [ recurrence viral copy antiviral treatment ] , patient cirrhosis ) . For patient , rule apply ensure telaprevir Peg-IFN-alfa/RBV stop subject viral breakthrough treatment failure . All patient follow visit ( include measurement hepatitis C viral RNA level bloodstream ) 24 week last administer dose treatment . Dose modification telaprevir prohibit telaprevir treatment discontinue may reinitiated study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>evidence hepatitis C virus infection genotype 1 ( molecular assay ) ; quantifiable plasma hepatitis C viral RNA level ; document liver fibrosis assess liver biopsy noninvasive test show severe fibrosis cirrhosis ( subject severe fibrosis , diagnostic test perform within past 18 month ) ; compensate liver disease ( ChildPugh Grade A clinical classification ) ; access hepatitis C treatment ( peginterferonalfa/ribavarin ) eligible enrollment ongoing clinical study telaprevir ; infect coinfected hepatitis C virus genotype genotype 1 and/or coinfected HIV ; contraindication administration peginterferonalfa ribavarin , medical history laboratory value preclude treatment peginterferonalfa ribavarin accord respective local prescribe information ; history previously receive investigational treatment hepatitis C viral protease polymerase inhibitor ( class drug like telaprevir ) ; sign symptoms hepatocellular carcinoma ( test serum alphafetoprotein ultrasonography do maximum 4 month screen screen hepetocellular carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>telaprevir</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>early access program</keyword>
</DOC>